Latest Biotech News

Intellia Therapeutics advanced its in vivo CRISPR program for hereditary angioedema, signaling potential FDA momentum after Phase 3 results. The company’s one-time lonvo-z treatment cut hereditary...

Eli Lilly agreed to acquire Ajax Therapeutics for up to $2.3 billion to expand its next-generation JAK franchise for myeloproliferative neoplasms. Lilly will gain access to AJ1-11095, a Type II...

Erasca reported preliminary efficacy data for its RAS-targeting oral drug ERAS-0015, reporting tumor shrinkage in 40% of patients with advanced pancreatic cancer and 62% of patients with advanced...

Compass Therapeutics shared additional results from its Companion-002 Phase 2/3 program for the DLL4/VEGF-A bispecific tovecimig in second-line biliary tract cancer. The new data included mixed...

Fred Hutchinson Cancer Center reported a transplantation approach using pooled umbilical cord blood stem cells that achieved a 96% survival rate and eliminated graft-versus-host disease in...

Oruka Therapeutics reported mid-stage psoriasis results for ORKA-001, an IL-23 monoclonal antibody with long-acting potential. In a Phase 2 trial, Oruka said 40 of 63 patients achieved PASI 100 at...

PlaqueTec raised $5 million in an oversubscribed financing round to support its coronary artery disease biomarker effort. The company is running a clinical trial called BIOPATTERN designed to...

Cepheid and other diagnostics players presented updates on rapid multiplex infectious disease testing at ESCMID, including workflow improvements designed to improve diagnostic stewardship....

An international clinical trial led by the University of British Columbia reported results in advanced atrial fibrillation that challenge the default approach of beginning with medication....

Whitehead Institute researchers reported a genome-wide screening platform to identify modifications in producer cells that improve the production and delivery potency of engineered virus-like...

Sun Pharmaceutical agreed to acquire Organon, the Merck spinoff women’s health and biosimilars business, in an all-cash $11.75B deal. The transaction is intended to push Sun toward a top three...

Erasca reported preliminary tumor-shrinking data for its RAS-targeting pill ERAS-0015 in advanced pancreatic and non-small cell lung cancer, describing results that exceeded its expectations. The...

Revolution Medicines’ lawyers issued a legal threat targeting Erasca’s RAS program, setting up the risk of a dispute over patents and efficacy claims. Erasca said it received the threat after a...

Intellia’s in vivo CRISPR therapy lonvo-z succeeded in a Phase 3 trial for hereditary angioedema, sharply reducing attack rates in patients with the rare swelling disorder. Intellia said it...

Researchers from Whitehead Institute reported a genome-wide screening approach to identify producer-cell modifications that improve production and delivery potency of engineered virus-like...

Eli Lilly agreed to acquire Ajax Therapeutics for up to $2.3B in cash to gain access to next-generation JAK2 inhibitor assets in myeloproliferative neoplasms. Lilly will receive Ajax’s lead...

Compass Therapeutics released additional results from its Companion-002 phase II/III study of tovecimig in combination with paclitaxel in second-line biliary tract cancer. The new update included...

Oruka Therapeutics reported mid-stage results for ORKA-001, a long-acting IL-23 monoclonal antibody, in plaque psoriasis and also provided updated exposure analysis supporting once-per-year...

PlaqueTec raised $5M in an oversubscribed round to expand its work on intracoronary blood-protein biomarkers for coronary artery disease. The company’s BIOPATTERN clinical trial uses a device that...

Clinical microbiologists warned at ESCMID that Europe’s IVDR implementation may reduce patient access to diagnostic tests and constrain development of new assays. Stakeholders cited real-world...